Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through September 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $58 million and $43 million respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At September 30, 2010, the Company had cash and cash equivalents of approximately $3 million. Based on its cash flow projections, the Company w
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Spherix Reports Second Quarter Earnings
    5. Tapestry Reports Second Quarter 2007 Results
    6. Callisto Reports on Second-Quarter 2007 Milestones
    7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    11. Biopure Reports on Meeting with the FDA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), today ... of the study presented by a prominent heart ... and concurrently published by the Journal of ... in patients with moderate to severe chronic heart ... the heart,s ability to pump blood, and reduces ...
    (Date:9/2/2014)... , Sept. 2, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood instrumentation and consumables to the medical, research ... , Chairman and Chief Executive Officer, will present at ... 10, 2014 at 10:20 a.m. ET. The conference will ... New York City . ...
    (Date:9/2/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today announced ... will present at the Morgan Stanley Global Healthcare Conference in ... York on Tuesday, September 9, 2014 at 12:20 ... listen to the live audio webcast of the presentation on ... An archive of the presentation will be available for replay ...
    Breaking Medicine Technology:ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
    ... Reportlinker.com announces that a new market research report ... European Markets for Interventional Cardiology Devices 2011 ... In 2010, the European markets ... euro1.5 billion. In 2010, the fastest growing European ...
    ... MOUNTAIN VIEW, Calif., April 7, 2011 /PRNewswire/ -- ... today announced the publication of results from the Phase ... in the peer-reviewed journal ,Headache., The manuscript, titled MAP0004, ... Acute Treatment of Migraine, has been posted online and ...
    Cached Medicine Technology:Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 2Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 3Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 4Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 5Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 6Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 7Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 8Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 9Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 10Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 11Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 12Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 13Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 14Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 15Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 16Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 17Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 18Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 19Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 20Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 21Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 2Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 3Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 4
    (Date:9/2/2014)... 2014 Cancer screening is a critical approach for ... more treatable. But while there are already existing ways ... a great need for even more safe, cheap and ... a team of researchers led by Shaoxin Li at ... of a new, non-invasive method to screen for prostate ...
    (Date:9/2/2014)... Warwick, R.I. (PRWEB) September 02, 2014 As ... analyze shifts in an industry and predict change. Fortunately for ... years, enabling him to identify markets that are eager for ... “My knowledge of the hearing aid market indicated it was ... to the consumer,” Sapio explained. As a result, he took ...
    (Date:9/2/2014)... in their work care for patients who are dying. ... that many nurses in training feel unprepared and anxious ... end-of-life care. , Scientists from the Sahlgrenska Academy have ... the University of Skvde and the Ersta Skndal University ... for dying patients, their ideas about how to support ...
    (Date:9/2/2014)... CA (PRWEB) September 02, 2014 ... and collaboration, announces partnership with NTT DoCoMo ... business customers. Splashtop Business Lite is included in ... is a remote desktop software that empower users to ... Splashtop has garnered over 18 million users worldwide. ...
    (Date:9/2/2014)... 2014 West Hollywood cosmetic dentist ... for Invisalign. This special offer includes a free consultation ... determine their candidacy for the procedure and answer any ... may also be eligible for the Summer Invisalign special, ... the month of August, patients who choose Invisalign will ...
    Breaking Medicine News(10 mins):Health News:New method for non-invasive prostate cancer screening 2Health News:David Sapio Launches Zounds Hearing Franchise 2Health News:Many nurses unprepared to meet dying patients 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2
    ... cheap, ruggedized forensics cameras will survive., , , ... , , ... , , , ... , , , , Lights, Camera, Ka-Boom! ...
    ... Makes Expo SplashPLEASANT GROVE, Utah, March 9 What,s ... Myo-Med ( www.myomed.com ), names like Tom Brady, LaDainian ... to truly helping people. Endorsements by professional athletes of ... these athletes actually used the product for a couple ...
    ... Stars at the Bal Harbour Shops Raised More Than ... - Seal and The Pointer Sisters Performed to a ... CollectionTommy Lee Jones, Gloria & Emilio Estefan, Anna Kournikova, ... Pat Riley Among the Stars in AttendanceMIAMI, March 9 ...
    ... Services, Inc. (NYSE: WST ) today announced that ... and William Federici, Chief Financial Officer, will be presenting at ... March 11, 2009 in Miami Beach. A copy of the ... of the Company,s website at www.westpharma.com and the ...
    ... following is a statement by Reverend Dr. Carlton ... for Reproductive Choice (RCRC) congratulates President Obama for ... funding of human embryonic stem cell research. This ... respects diverse religious and moral views and a ...
    ... 9 Speaker Nancy Pelosi issued the following ... lifting the Bush Administration,s restrictions on federally financed human ... on federal funding for stem cell research, President Obama ... family in America is just one diagnosis, one phone ...
    Cached Medicine News:Health News:Ka-Boom!!! 2Health News:Ka-Boom!!! 3Health News:Ka-Boom!!! 4Health News:Tom Brady Endorsed Pain Cream Returns to Natural Products Expo 2Health News:Destination Fashion 2009 Presented by Stewart Rahr - 2Health News:Destination Fashion 2009 Presented by Stewart Rahr - 3Health News:Religious Coalition for Reproductive Choice President Applauds Obama Stem Cell Policy 2
    ... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
    ... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
    Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
    ... Plasma Reagin card test ... and quantitative determination of ... plasma. Uses carbon particle ... reagin. Kits include 10-well ...
    Medicine Products: